Market cap
$3,806 Mln
Recently Viewed
Clear All$76.01
$0.00 (0.00%)As on 07-Sep-2022 09:30EDT
Market cap
$3,806 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
4.8
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-342 Mln
ROE
-0.4 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-8.8
Debt to Equity
0
Book Value
$--
EPS
$-6.9
Face value
--
Shares outstanding
50,074,300
CFO
$-330.61 Mln
EBITDA
$-505.80 Mln
Net Profit
$-507.35 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Turning Point Therapeutics (TPTX)
| 59.4 | 1.4 | 1.7 | -4.7 | 21.1 | -- | -- |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
|---|---|---|
|
Turning Point Therapeutics (TPTX)
| -60.9 | 95.6 |
|
S&P Small-Cap 600
| 25.3 | 9.6 |
|
BSE Sensex
| 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Turning Point Therapeutics (TPTX)
|
76.0 | 3,806.2 | 1.0 | -342.3 | -33,130.6 | -39.2 | -- | 4.8 |
| 0.3 | 53.5 | 0.0 | -24.2 | -- | -30.1 | -- | 0.7 |
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that... targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company. Read more
Pres, CEO & Director
Dr. Athena Maria Countouriotis M.D.
Pres, CEO & Director
Dr. Athena Maria Countouriotis M.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Turning Point Therapeutics Inc (TPTX) is $76.01 (NASDAQ) as of 07-Sep-2022 09:30 EDT. Turning Point Therapeutics Inc (TPTX) has given a return of 21.15% in the last 3 years.
Since, TTM earnings of Turning Point Therapeutics Inc (TPTX) is negative, P/E ratio is not available.
The P/B ratio of Turning Point Therapeutics Inc (TPTX) is 4.80 times as on 07-Sep-2022, a 3 discount to its peers’ median range of 4.96 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-9.88
|
2.45
|
|
2020
|
-31.76
|
4.50
|
|
2019
|
-20.73
|
3.70
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Turning Point Therapeutics Inc (TPTX) are Rs -- and Rs -- as of 02-May-2026.
Turning Point Therapeutics Inc (TPTX) has a market capitalisation of $ 3,806 Mln as on 07-Sep-2022. As per SEBI classification, it is a Small Cap company.
Before investing in Turning Point Therapeutics Inc (TPTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.